ID: ALA3086046

Max Phase: Preclinical

Molecular Formula: C36H37ClN2O

Molecular Weight: 549.16

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1ccccc1[C@H]1C[C@H](NCc2ccc(Cl)cc2)CC[C@@H]1C(=O)N1CC(c2ccccc2)(c2ccccc2)C1

Standard InChI:  InChI=1S/C36H37ClN2O/c1-26-10-8-9-15-32(26)34-22-31(38-23-27-16-18-30(37)19-17-27)20-21-33(34)35(40)39-24-36(25-39,28-11-4-2-5-12-28)29-13-6-3-7-14-29/h2-19,31,33-34,38H,20-25H2,1H3/t31-,33+,34-/m1/s1

Standard InChI Key:  IIXUBHOQXODODU-PNIVXLCQSA-N

Associated Targets(Human)

Lysosomal Pro-X carboxypeptidase 567 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Lysosomal Pro-X carboxypeptidase 241 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 549.16Molecular Weight (Monoisotopic): 548.2594AlogP: 7.52#Rotatable Bonds: 7
Polar Surface Area: 32.34Molecular Species: BASEHBA: 2HBD: 1
#RO5 Violations: 2HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 9.43CX LogP: 7.86CX LogD: 5.85
Aromatic Rings: 4Heavy Atoms: 40QED Weighted: 0.26Np Likeness Score: -0.32

References

1. Debenham JS, Graham TH, Verras A, Zhang Y, Clements MJ, Kuethe JT, Madsen-Duggan C, Liu W, Bhatt UR, Chen D, Chen Q, Garcia-Calvo M, Geissler WM, He H, Li X, Lisnock J, Shen Z, Tong X, Tung EC, Wiltsie J, Xu S, Hale JJ, Pinto S, Shen DM..  (2013)  Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.,  23  (23): [PMID:24157366] [10.1016/j.bmcl.2013.09.094]
2. Debenham JS, Graham TH, Verras A, Zhang Y, Clements MJ, Kuethe JT, Madsen-Duggan C, Liu W, Bhatt UR, Chen D, Chen Q, Garcia-Calvo M, Geissler WM, He H, Li X, Lisnock J, Shen Z, Tong X, Tung EC, Wiltsie J, Xu S, Hale JJ, Pinto S, Shen DM..  (2013)  Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.,  23  (23): [PMID:24157366] [10.1016/j.bmcl.2013.09.094]

Source